Dallas Drugs Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
- Paid Up Capital ₹ 2.50 Cr
- Company Age 12 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 11.28 Cr
- Revenue Growth -18.72%
- Profit Growth 105.72%
- Ebitda 626.51%
- Net Worth 17.34%
- Total Assets -11.10%
About Dallas Drugs
Dallas Drugs Private Limited (DDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 25 April 2012 and has a history of 12 years and ten months. Its registered office is in Chandigarh, India.
The Corporate was formerly known as Friska Foods Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.50 Cr.
The company currently has active open charges totaling ₹11.28 Cr.
Rajesh Gupta and Anil Kumar serve as directors at the Company.
Company Details
- Location
Chandigarh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U15400CH2012PTC033748
- Company No.
033748
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Apr 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Dallas Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Kumar  | Director | 29-Sep-2018 | Current |
| Rajesh Gupta | Director | 29-Sep-2018 | Current |
Financial Performance of Dallas Drugs.
Dallas Drugs Private Limited, for the financial year ended 2024, experienced significant reduction in revenue, with a 18.72% decrease. The company also saw a substantial improvement in profitability, with a 105.72% increase in profit. The company's net worth Soared by an impressive increase of 17.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dallas Drugs?
Unlock access to Dallas Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Dallas Formulations Private LimitedRajesh Gupta is a mutual person
Himachal Pharma Testing Lab LimitedRajesh Gupta is a mutual person
Charges (Loans)
₹11.28 Cr
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 11.28 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Apr 2019 | State Bank Of India | ₹11.28 Cr | Open |
How Many Employees Work at Dallas Drugs?
Dallas Drugs has a workforce of 23 employees as of Dec 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dallas Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dallas Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
